What is WHPM?
W.H.P.M., Inc. operates as a key player in the medical diagnostic market, specializing in a diverse portfolio of products. Their offerings include Drugs of Abuse Tests, Harm Reduction Tests, Automated FIT Tests, and Fertility Diagnostic Tests. Beyond product development, WHPM provides essential private labeling and contract manufacturing services, empowering distribution partners to enhance their market competitiveness. The company's strategic focus on cutting-edge research and advanced manufacturing capabilities positions it to deliver innovative solutions to its clientele. WHPM is slated to exhibit its latest advancements at the ADLM 2026 trade fair in Anaheim, California, further solidifying its industry presence.
How much funding has WHPM raised?
WHPM has raised a total of $407K across 2 funding rounds:
Debt
$150K
Debt
$257K
Debt (2020): $150K with participation from PPP
Debt (2021): $257K led by PPP
Key Investors in WHPM
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for WHPM?
The recent large-scale, late-stage funding, characterized as a major strategic investment, indicates that WHPM is poised for significant expansion and market penetration. This capital infusion is likely to fuel advancements in product development, enhance manufacturing capacity, and potentially broaden its distribution network. The company's commitment to innovation, as evidenced by its R&D focus and upcoming trade show presence, suggests a strategic roadmap aimed at capturing greater market share within the competitive medical diagnostics sector. Future growth may involve scaling operations to meet increasing demand and exploring new therapeutic areas or diagnostic technologies.
See full WHPM company page
